Fig. 3From: PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialForest plot of neratinib vs placebo in PIK3CA-altered and hormone receptor subgroups. HRc, hormone receptorBack to article page